SCHEMBL22001541

SCHEMBL22001541

CCN(CC)c1ccc2cc(/C(C)=N/OC(=O)c3ccc([N+](=O)[O-])cc3)c(=O)oc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 11/20 0.56
▸ KMT2A Q03164 11/20 0.56
▸ MAPT P10636 10/20 0.56
▸ MAOB P27338 3/20 0.56
▸ ATM Q13315 2/20 0.56
▸ USP2 O75604 1/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ HPGD P15428 5/20 0.55
▸ ALDH1A1 P00352 5/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ KDM4E B2RXH2 5/20 0.53
▸ SLC16A3 O15427 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ SLC16A1 P53985 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ LMNA P02545 3/20 0.49
▸ HTT P42858 2/20 0.49
▸ XDH P47989 1/20 0.48
▸ CTDSP1 Q9GZU7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22001518 0.87 MAOB (0.69) MEN1KMT2AMAPTMAOBATM
SCHEMBL11095760 0.84 MAOB (0.72) MEN1KMT2AMAPTMAOBATM
SCHEMBL22001534 0.83 MEN1 (0.70) MEN1KMT2AMAPTMAOBATM
SCHEMBL22059590 0.78 MEN1 (0.70) MEN1KMT2AMAPTMAOBATM
SCHEMBL22001542 0.77 MEN1 (0.61) MEN1KMT2AMAPTMAOBATM
SCHEMBL21404699 0.75 MAOB (0.76) MEN1KMT2AMAPTMAOBATM
SCHEMBL1131018 0.73 MEN1 (1.00) MEN1KMT2AMAPTMAOBATM
SCHEMBL29460450 0.73 MEN1 (1.00) MEN1KMT2AMAPTMAOBATM
SCHEMBL9099780 0.73 CYP19A1 (0.68) MEN1KMT2AMAPTMAOBATM
SCHEMBL2911015 0.73 MAOB (0.80) MEN1KMT2AMAPTMAOBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11142511-B2 Coumarin oxime ester compounds, preparation and use thereof HUBEI GURUN TECHNOLOGY CO., LTD. (CN) 2021-10-12 — — US disclosed
EP-3660008-A1 COUMARIN OXIME ESTER COMPOUND AND PREPARATION AND USE THEREOF Hubei Gurun Technology Co., Ltd (CN) 2020-06-03 — — EP disclosed
US-20200148660-A1 COUMARIN OXIME ESTER COMPOUNDS, PREPARATION AND USE THEREOF HUBEI GURUN TECHNOLOGY CO. LTD (CN) 2020-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148660-A1 COUMARIN OXIME ESTER COMPOUNDS, PREPARATION AND USE THEREOF CBR3, POR, CYP3A4 MEN1 3755/4885KMT2A 1311/4885MAPT 1764/4885
US-11142511-B2 Coumarin oxime ester compounds, preparation and use thereof CBR3, POR, CYP3A4 MEN1 3755/4885KMT2A 1311/4885MAPT 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback